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Abstract
According to the cancer stem cell (CSC)/cancer-initiating cell hypothesis, glioma development is driven by a sub-
population of cells with unique tumor-regenerating capacity. We have characterized sphere-cultured glioma-
derived cancer-initiating cells (GICs) from experimental gliomas induced by platelet-derived growth factor-B
(PDGF-B) in neonatal Gtv-a Arf−/− mice. We found that the GICs can maintain their stem cell–like characteristics
in absence of exogenous epidermal growth factor and fibroblast growth factor 2 and that this culture condition
was highly selective for tumor-initiating cells where as few as five GICs could induce secondary tumor formation
after orthotopic transplantation. Addition of FBS to the medium caused the GICs to differentiate into cells coex-
pressing glial fibrillary acidic protein and Tuj1, and this differentiation process was reversible, suggesting that the
GICs are highly plastic and able to adapt to different environments without losing their tumorigenic properties. On
inhibition of virally transduced PDGF-B by small interfering RNA treatment, the GICs stopped proliferating, lost their
self-renewal ability, and started to uniformly express CNPase, a marker of oligodendrocyte precursor cells and
mature oligodendrocytes. Most importantly, PDGF-B depletion completely abrogated the tumor-initiating capacity
of the GICs. Our findings suggest that interfering with PDGF-controlled differentiation could be a therapeutic ave-
nue for patients diagnosed with the PDGF-driven proneural subtype of human glioblastoma.
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Introduction
Glioma is the most frequent primary tumor of the central nervous
system. Gliomas are divided into grades 1 to 4 based on malignancy
according to the World Health Organization classification. The prog-
nosis of a grade 4 glioma, glioblastoma, remains dismal with a median
survival of about 12 to 15 months, and there is as yet no cure [1].
Large-scale genomic characterization of human glioblastoma has re-
vealed three core signaling pathways that are altered in most tumors:
the receptor tyrosine kinase (RTK)/RAS/PI3K, the p53, and the RB
signaling pathways [1,2]. The most common alterations leading to
activation of RTKs are EGFR amplifications and PDGFRA amplifica-
tions. Further, global gene expression analysis has revealed four new
subclasses of glioblastoma based on their expression profiles: pro-
neural, neural, classic, and mesenchymal [3]. The proneural subtype
is associated with PDGFRA abnormalities and IDH1 and TP53 mu-
tations. This group also has a high expression of genes involved in
oligodendrocytic development such as OLIG2 and SOX2. Unlike
the classic subtype, associated with high-level EGFR amplification
and frequent CDKN2A deletion, and the mesenchymal subtype, asso-
ciated with frequent NF1 deletions, where mortality was significantly
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reduced in response to intense chemotherapy and radiotherapy, the
proneural subtype did not respond well to these therapies [3].
A large body of evidence has emerged suggesting that human glioma
contains glioma-derived cancer-initiating cells (GICs), a minor cell
population with unique capacity to regenerate brain tumors in vivowith
maintained characteristics of the primary tumor. GICs express many
markers associated with neural stem cells (NSCs) such as nestin,
SOX2, Bmi-1, Notch, and Jagged [4–7]. When cultured under stem cell
conditions, GICs have the capacity of extended self-renewal as spheres,
as well as the ability to differentiate into multiple neural cell lineages
in vitro. Initially, GICs were isolated based on CD133 expression, which
was believed to be a uniquemarker for GICs [6]. Subsequent studies have
shown that there are both CD133+ and CD133− GICs, thus CD133 is
not an obligatory marker for GICs [8,9]. GICs have been shown to have
increased resistance to radiotherapy by activation of the DNA damage
response pathway [10] and to chemotherapy through efflux of drugs
through the ABCG2 transporter [11]. Collectively, this makes GICs a
vital target for new therapeutic strategies for glioma.
The central role of platelet-derived growth factor (PDGF) in the
development of glioma suggests that PDGF signaling is important
for GIC initiation and maintenance. We have studied the properties
of GICs derived from experimental gliomas that show many similari-
ties to the proneural subtype of glioblastoma. We used the RCAS/
TV-A (replication-competent avian leukosis virus splice acceptor/
avian leukosis virus receptor) somatic cell gene transfer mouse model
of glioma, and intracerebral tumors were induced by RCAS-PDGF-B
in neonatal Gtv-a (GFAP-tv-a) Arf −/− mice. Generated gliomas dis-
play histopathologic features of glioblastoma and expression of
PDGFRA, OLIG2, and SOX2 that are connected to the proneural
subtype of glioblastoma [12]. GICs were isolated and cultured as
neurospheres in defined medium without addition of growth factors.
As reference cells, normal NSCs were isolated from Gtv-a Arf −/−
mice and cultured in defined NSC medium. The role of PDGF sig-
naling for fundamental features of GICs such as self-renewal, prolif-
eration, differentiation, and in vivo tumorigenesis has been studied,
and we show that PDGF-B is necessary for stemness and tumorige-
nicity of GICs by preventing them from differentiating.
Materials and Methods
Infection of Transgenic Mice
Gtv-a Arf −/− mice were used to generate the primary brain tumors.
Neonatal mice were injected in the right cerebral hemisphere with
2 μl of DF-1 chicken fibroblasts producing RCAS-PDGFB-HA as de-
scribed [13]. Infected mice were monitored every second day and killed
on any sign of illness. All animal experiments were performed in accor-
dance with the rules and regulations of Uppsala University and were
approved by the local animal ethics committee.
Histopathology and Immunofluorescence Analyses of Tumors
The brains of sick mice were taken out and cut coronally at the
injection site. The anterior piece was used for neurosphere culture.
For primary tumors, the posterior piece was fixed in 4% paraformal-
dehyde for 1 hour, then cryoprotected in 30% sucrose overnight,
both at 4°C, and finally embedded in OCTand frozen. The posterior
piece from secondary tumors was fixed in 4% formalin for at least
48 hours, embedded in paraffin, sectioned, and analyzed for the
presence of tumor tissue by viewing hematoxylin and eosin
(H&E)–stained sections. Tissue sections were blocked in PBS contain-
ing Triton X-100 (PBS-T) and 5% milk. Primary antibodies against
HA (1:100; Abcam, Cambridge, UK), Ki67 (1:100; Dako, Glostrup,
Denmark), Olig2 (1:200; Millipore, Temecula, CA), Nestin (1:200;
BD Bioscience, Franklin Lakes, NJ), and glial fibrillary acidic protein
(GFAP; 1:400; Dako) were incubated in blocking solution at 4°C
overnight. The sections were then washed with PBS-T three times
and incubated with secondary antibodies donkey antirabbit Alexa 488
(1:400; Invitrogen, Carlsbad, CA), donkey antimouse Alexa 555
(1:400; Invitrogen), and goat antirat Alexa 555 (1:400; Invitrogen) in
PBS-T at room temperature for 1 hour. After final washing three times
in PBS-T, sections were mounted in Immu-mount (Thermo-Scientific,
Waltham, MA) with 4′,6-diamidino-2-phenylindole.
Neurosphere Culture
Tumor tissue was extracted using a scalpel, trying to remove as
much of the normal tissue as possible, minced with the scalpel,
and incubated in Accutase (eBioscience, San Diego, CA) for 15 min-
utes at 37°C. Tissue pieces were washed three times in Dulbecco
modified Eagle medium (DMEM; Sigma, Hamburg, Germany) fol-
lowed by trituration using a 1000-μl pipette. Cells were passed
through a 70-μm cell strainer and seeded into six-well tissue culture
plates. Cells were grown in GIC medium containing DMEM-F12
GlutaMAX (GIBCO-Invitrogen), 1% penicillin G/streptomycin sul-
fate (Sigma), B-27 without vitamin A (1:50; GIBCO-Invitrogen),
HEPES (0.2 mM; Sigma), and insulin (20 ng/ml; Sigma). Spheres
were passaged by trituration through a 1000-μl pipette and reseeded
into fresh medium. Sphere cultures below passage 25 were used for
all analyses described in this article. As reference cells, brain tissue
from uninjected Gtv-a Arf −/− mice was dissociated the same way as
the tumor tissue. NSCs were cultured in NSC medium, which is
GIC medium supplemented with fibroblast growth factor 2 (FGF2,
20 ng/ml; PeproTech, Rocky Hill, NJ) and epidermal growth factor
(EGF, 20 ng/ml; PeproTech).
Intracranial Cell Transplantation into Syngeneic Mice
Spheres were dissociated by trituration through a 1000-μl pipette,
and the number of cells was determined using a Coulter Counter
(Coulter Electronics, Herpendon, UK). The appropriate number of
cells was resuspended in of DMEM/F12 medium to reach a total cell
count of 5, 50, 500, and 5000 (tumor cells) or 500,000 (control
cells) per 2-μl medium, respectively. From these aliquots, 2 μl was
orthotopically injected into neonatal syngeneic mice. Injected mice
were monitored every second day. The brains of sick mice were taken
out and subjected to histopathology analyses as described previously.
Sphere-Forming Assay
Spheres were dissociated into single cells and seeded at a density of
50 cells/well in a 96-well plate under different culture conditions.
The cells were left undisturbed and cultured for 7 days. On day 7,
pictures of cultured cells were taken using a phase-contrast micro-
scope (Olympus Europa GmbH, Hamburg, Germany). The experi-
ment was repeated twice.
Limiting Dilution Assay
Limiting dilution assay was performed as described previously
[14]. Spheres were dissociated into single cells and plated in 96-well
plates in 0.2 ml of GIC medium containing different combinations
of growth factors. Final cell numbers ranged from 400 cells/well to
1 cell/well. Cultures were left undisturbed for 10 days, and then the
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percentage of wells not containing spheres for each cell dilution was
calculated and plotted against the number of cells per well. Linear
regression lines were plotted, and the number of cells required to
generate at least one sphere in every well (=the stem cell frequency)
was calculated. The experiment was repeated twice.
Differentiation Assay
Small spheres (formed after 2 days of passaging) were seeded onto
extracellular matrix– (1:5; Sigma) coated glass coverslips in individual
wells of a 24-well plate. The cells were cultured in NSC medium,
GIC medium, or GIC medium with 5% FBS (Sigma) for 7 days be-
fore analysis. Medium was changed once after 3 to 4 days of cultur-
ing. For quantification of cell markers, more than 300 cells for each
condition were counted. The experiment was repeated three times.
In the differentiation reversibility assay, bromodeoxyuridine (BrdU)
was added 16 hours before fixation.
RNA Interference of Viral Produced Human PDGF-B
Small spheres were dissociated into single cells and seeded into
six-well plates. Cells were transfected with control small interfering
RNA (siRNA) or siRNA against human PDGF-B messenger RNA
(Dharmacon, Lafayette, CO) that was specifically selected not to hy-
bridize to mouse PDGF-Bmessenger RNA. Transfection was performed
according to the manufacturer’s manual. Forty-eight hours after transfec-
tion, cells were either dissociated and seeded for limiting dilution assay or
seeded on ECM- (1:5; Sigma) coated glass coverslips for a second round
of transfection. These cells were fixed after another 48 hours of transfec-
tion in 4% paraformaldehyde, and immunofluorescence analysis was
performed. BrdU was added to the cells 16 hours before fixation. For
BrdU quantification, more than 300 cells were counted for each trans-
fection. The experiment was repeated three times.
Immunocytochemical Analyses
Cells were fixed in 4% paraformaldehyde for 10 minutes. After
washing in PBS, cells were treated with 0.2% Triton X-100 and
blocked for 1 hour in a solution containing 1% BSA and 5% normal
goat serum. Primary antibodies against GFAP (1:400; Dako), Tuj1
(1:400; Covance, Princeton, NJ), CNP (1:400; Covance), nestin
(1:100; BD Bioscience), SOX2 (1:500; Millipore), HA (1:40; Santa
Cruz Biotechnologies, Santa Cruz, CA), PDGFRα (1:100; Santa
Cruz Biotechnologies), BrdU (1:100; Abcam), Ki67 (1:100; Dako), or
Caspase-3 (1:100; Chemicon, Billerica, MA) were incubated overnight
in a humidified chamber at 4°C. Coverslips were washed three times in
PBS and incubated with the secondary antibodies donkey antirabbit
Alexa 488 (1:400; Invitrogen), donkey antimouse Alexa 555 (1:400;
Invitrogen), and goat antirat (1:400; Invitrogen) for 1 hour at room tem-
perature. Coverslips were then washed three times in PBS and mounted
in Immu-mount (Thermo-Scientific) containing 0.1% DAPI.
Results
GIC Self-renewal In Vitro Was Independent
of Exogenous Mitogens
To investigate the properties of experimental GICs, gliomas were
induced with RCAS-PDGFB-HA in neonatal Gtv-a Arf −/− mice.
The Arf −/− background was chosen because it is one of the most
common mutations of human glioblastoma found in more than
50% of proneural tumors [3], and in experimental gliomas, it in-
creases tumor incidence and malignancy [12]. Until now, most stud-
ies on experimental and human GICs have been carried out under
the same culture conditions as for normal NSCs, that is, in defined
medium containing EGF and FGF2 [14]. However, NSCs are prone
to migrate toward glioma lesions [15] making it difficult to avoid
contaminating the GIC cultures with NSCs. In our initial experi-
ments, explanted tumor cells were cultured under regular NSC con-
ditions, but we soon experienced, by staining for HA (expression of
retroviral PDGF-B) that, after a few passages, normal NSCs had
completely taken over the culture (data not shown). On removal
of EGF and FGF2 from the NSC medium, we found that the GICs
could be enriched for and stably maintained. Therefore, in this in-
vestigation, we have used tumor sphere cultures derived from PDGF-
B–induced glioblastoma-like tumors cultured in GIC medium (NSC
medium without EGF and FGF2). Spheres could be observed after
7 days in cultures from five different tumors (TS1-TS5). The TS1 and
TS2 cells were used throughout this investigation. As reference cells,
we have used neurospheres (NS1) derived from uninjectedGtv-a Arf −/−
mice. The NS1 cells were cultured in NSCmedium because they could
not be established or expanded in GIC medium or GIC medium with
addition of exogenous PDGF-BB.
To analyze the self-renewal capacity of NSCs and GICs in response
to different combinations of exogenous growth factors, NS1 and TS1
cells were seeded at clonal density (1000 cells/ml) in GIC medium
with or without the addition of EGF, FGF2, or PDGF-BB (Figure 1,
A–I ). After 7 days, NS1 cells had the ability to form spheres only
when EGF was present (Figure 1, A–E ). TS1 cells, however, could
form spheres under all conditions (Figure 1, F–I ).
Limiting dilution assay was performed to estimate the stem cell fre-
quency of TS1 and NS1 cultures under the same conditions as in the
sphere formation assay. The number of NS1 cells required to generate
at least one sphere/well was around 8 for both EGF and EGF + FGF2
(Figure 1J ) and 9 for TS1 cells in all conditions tested: EGF, EGF +
FGF2, FGF2, and no growth factors (Figure 1K ). Thus, the tumor-
derived cells and the corresponding normal NSCs contained similar
frequencies of cells with self-renewal capacity, but the tumor-derived
cells could be distinguished from the NSCs by their ability to self-
renew independently of exogenous EGF and FGF2.
The mechanism behind the growth factor independence of TS
cells was investigated by analyzing PDGFR-α and PDGFR-β expres-
sion in NS1 and TS1 cells. No PDGF receptors were expressed by
the NS1 cells (Figure 1, L and N ), explaining why NS1 cells could
not respond to exogenous PDGF-B (Figure 1E ). In contrast, TS1
cells expressed high levels of PDGFR-α (Figure 1M ) but had no ex-
pression of PDGFR-β (Figure 1O).
Tumor-Derived Sphere Cells Could Induce Secondary Gliomas
A fundamental characteristic of CSCs/cancer-initiating cells
(CICs) is that they must be able to generate secondary tumors on
orthotopic transplantation. To analyze the tumor-initiating ability
of the tumor-derived cells, TS1 cells were orthotopically transplanted
into newborn syngeneic mice. Spheres from TS1 cells were dissociated
into single cells, and 5, 50, 500, or 5000 cells were injected intra-
cerebrally after which the mice were monitored for 12 weeks
(Figure 1P). Mice that had received 5000 TS1 cells (n = 10) started
to show signs of illness 20 days after transplantation, and all mice
presented with tumors within 40 days. On injection of 500 TS1 cells
(n = 10), 90% of the mice developed tumors, and the latency was
longer. Injection of 50 TS1 cells (n = 14) caused a tumor incidence
of 21% and injection of 5 TS1 cells (n = 12) initiated tumors in 33%
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of the mice. In contrast, mice injected with 500,000 NSCs (NS1)
were 100% tumor free after 12 weeks of injection (n = 6). There
was a significant difference in survival between NS1-injected mice
and mice injected with 5000 TS1 cells (Fisher exact test, P =
.0003) or 500 TS1 cells (Fisher exact test, P = .0011), respectively.
Histopathologic analysis of the primary tumor from which the
TS1 cells were derived (Figure W1A) and the secondary tumors gener-
ated by TS1 cells (Figure W1B) showed several features of glioblastoma
including areas of pseudopalisading necrosis (Figure W1A, H&E) and
microvascular proliferations (Figure W1B, H&E). All secondary tumors
were of grade 4 malignancy with high cellular density. Immunostainings
of the primary tumor and one representative secondary tumor showed
that both were positive for HA (Figure W1, A and B, HA), confirming
that the secondary tumor had originated from the transplanted TS1
Figure 1. Self-renewal, stem cell frequency, and tumorigenicity of glioma-derived tumor sphere cells. (A-I) Sphere-forming assay show-
ing the ability of NSCs (A-E; NS1 cells) and TS1 (F-I) cells to generate spheres in GIC medium containing different combinations of
growth factors. Scale bar, 50 μm. (J-K) The result from the limiting dilution assay showing linear regression curves to determine the
stem cell frequency in NS1 (J) and TS1 (K) cells. The experiments were repeated twice. (L-O) Immunofluorescence staining for PDGFR-α
and PDGFR-β in NS1 and TS1 cells. Scale bar, 50 μm. (P) Kaplan-Meier graph showing survival of Gtv-a Arf−/− mice orthotopically trans-
planted with 5000, 500, 50, or 5 TS1 cells or 500,000 NS1 cells. Log-rank test, **P < 0.01, ***P < 0.001.
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cells. Primary and secondary tumors were Ki67 positive, with notably
more positive cells in the secondary tumor (FigureW1, A and B, Ki67).
Tumors were also positive for Olig2, nestin, and GFAP (Figure W1, A
and B). Because the glioma-derived TS1 cells were highly capable of
inducing brain tumors with many features similar to the primary tu-
mor, they could be regarded as true GICs.
GICs Exhibited Aberrant Differentiation Capacity
In addition to extended self-renewal and tumor-initiating capabil-
ities, GICs should hold the potential to differentiate into glial and
neuronal cell types. First, we analyzed the expression of NSC markers
nestin and SOX2 in GICs and NSCs. Small spheres of NS1, TS1,
and TS2 cells were seeded onto ECM-coated coverslips and cultured
for 7 days in NSC medium, GIC medium, or GIC medium with ad-
dition of 5% fetal bovine serum. Serum has previously been used to
show that human GICs are capable of multilineage differentiation
[5]. Cells migrated out from the neurospheres and formed a mono-
layer on the coverslips that could be subjected to immunofluorescence
analyses. When NSCs and GICs were cultured in NSC medium,
they exhibited an immature, bipolar morphology and were strongly
Figure 2. Expression of nestin and SOX2 in representative samples of NS1 and TS1 cells under different culture conditions for 7 days.
NSCs cultured in NSC medium (A), GIC medium (B), or GIC medium + 5% FBS (C) and GICs cultured in NSC medium (D), GIC medium
(E), or GIC medium + 5% FBS (F). Scale bar, 50 μm.
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positive for both nestin and SOX2 (Figure 2, A and D). On EGF and
FGF withdrawal (GIC medium) or in GIC medium with addition of
5% FBS, NS1 cells displayed an enlarged, flattened morphology and
became negative for nestin (Figure 2, B and C ). Also, SOX2 expres-
sion was clearly downregulated in the NS1 cells (Figure 2, B and C ).
In contrast, TS1 and TS2 cells retained the same levels of nestin and
SOX2 in GIC medium compared to NSC medium (Figure 2E). On
addition of 5% FBS to the GIC medium, TS1 and TS2 cells displayed
the same enlarged morphology as the NS1 cells and became negative
for nestin. SOX2 expression was, however, maintained in many cells
(Figure 2F).
Next, we analyzed the expression of the neuronal marker Tuj1,
the astrocytic marker GFAP, and the oligodendrocyte progenitor
cell/oligodendrocyte marker CNPase in NSCs and GICs. GICs have
been shown to exhibit abnormal differentiation abilities often result-
ing in cells that coexpress astrocytic and neuronal markers [7], which
is rare for NSCs. NS1 cells that were cultured in NSC medium were
negative for GFAP, CNPase, and Tuj1 (Figure 3, A and G ). On EGF
and FGF withdrawal or in GIC medium with 5% FBS, the number
of GFAP- and Tuj1-positive cells increased, but there were no cells
positive for CNPase (Figure 3, B and C and H and I ). A quanti-
fication showed that, in GIC medium, 89% of NSCs were GFAP
positive, 10% were Tuj1 positive, and only very few NS1 cells were
GFAP and Tuj1 double positive (Figure 3M ). Addition of 5% FBS
caused a decreased frequency of GFAP-positive cells (69%) and in-
creased the frequency of GFAP and Tuj1 double positive cells to 15%
(Figure 3N ). The result from GICs showed that very few TS1 and
TS2 cells expressed GFAP, Tuj1, and CNPase in NSC and GIC
medium (Figure 3, D–F and J–L), indicating their stem cell–like
state also under EGF- and FGF2-free conditions. By adding FBS
to the medium, both TS1 and TS2 cells exhibited an altered GFAP
and Tuj1 expression pattern compared with NS1 cells. Most cells
(74% of TS1 and 82% of TS2) became double positive for GFAP
and Tuj1 (Figure 3N ). As for the NS1 cells, only rare CNPase single
positive cells could be found.
Our data show that the GICs could maintain their stem cell–like
properties when cultured as spheres in the absence of exogenous EGF
and FGF2 and that they were capable of expressing multiple lineage
markers on addition of FBS. However, their differentiation ability
was abnormal, with a large proportion of cells being double positive
for both astrocytic and neuronal markers, a feature that was rare in
the serum-differentiated NSCs.
Serum-Induced Differentiation of GICs Was Reversible
The fact that most serum-differentiated GICs were double positive
for GFAP and Tuj1 indicated that aberrant differentiation had oc-
curred. Because terminal differentiation of GICs could be an avenue
Figure 3. Expression of Tuj1, GFAP, and CNPase in representative samples of NS1 and TS1 cells cultured under different conditions for
7 days. Expression of GFAP and Tuj1 in NS1 (A-C) and TS1 (D-F) cells. Expression of GFAP and CNPase in NS1 (G-I) and TS1 (J-L) cells.
Quantification of CNPase-, GFAP-, Tuj1-, and GFAP + Tuj1–positive cells in GIC medium (M) or GIC medium + 5% FBS (N). The exper-
iment was repeated three times. Values represent the mean ± SD. Scale bar, 50 μm.
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for therapy, we were interested to analyze if this process was reversible
or irreversible and to investigate if the serum-differentiated cells con-
tinued to proliferate. To test this, we used TS1 cells that had been
cultured in GIC medium + 5% FBS for 7 days that displayed the
typical enlarged, flattened morphology and put them back in GIC
medium for 7 days. Already at day 1 in GIC medium, cells started
to curl up and lose attachment to the dish (Figure 4A). All cells ex-
pressed the viral transduced human PDGF-B as analyzed by HA
staining and approximately 50% of the cells were incorporating
BrdU (Figure 4B). Barely any cells expressed Nestin, but SOX2 ex-
pression was retained in approximately 50% of the cells (Figure 4C )
and most cells were strongly positive for GFAP and Tuj1 (Figure 4D).
At day 7, TS1 cells had reverted entirely, and all cells grew as spheres
(Figure 4E ) and expressed PDGF-B (Figure 4F ) and most cells were
BrdU positive (Figure 4F). Moreover, the cells had regained a high ex-
pression of Nestin and SOX2 (Figure 4G) and completely lost GFAP
and Tuj1 expression (Figure 4H ), indicating a complete reversion into
a stem cell–like state again. Overall, they appeared indistinguishable
to cells that had never been subjected to serum (Figure 2E ). As ref-
erence cells, we used GICs that were maintained in GIC medium +
5% serum for another 7 days. These cells retained a differentiated
morphology (Figure 4I ), expressed GFAP and Tuj1 (Figure 4L), and
were negative for nestin, as shown before (Figure 2F ). However, the
serum-differentiated TS1 cells were highly proliferative (Figure 4J )
and continued to express PDGF-B (Figure 4J) and SOX2 (Figure 4K ),
although the PDGF-B expression was somewhat decreased in most
cells, clearly establishing that serum could not induce terminal differ-
entiation of our GICs.
Figure 4. Reversibility of serum-induced differentiation of TS1 cells cultured in GIC medium + 5% serum for 7 days and after that in GIC
medium for 24 hours (A-D), or GIC medium for 7 days (E-H), or GIC medium + 5% FBS (reference cells) for 7 days (I-L). (A, E, I) Phase-
contrast showing cell morphology and expression of HA (tag on viral transduced PDGF-B) and Brdu (B, F, J), SOX2 and nestin (C, G, K),
and GFAP and Tuj1 (D, H, L). Scale bar, 50 μm.
Figure 5. Analysis of self-renewal, proliferation, and apoptosis on PDGF-B knockdown in GICs. (A-B) Expression of HA and Brdu in TS1
cells transfected with control (A) or PDGF-B (B) siRNA. (C) Total number of GICs after siRNA treatment. The experiment was repeated
three times. Values represent the mean ± SD. Student’s t test, *P < 0.05, ***P < 0.001. (D) Stem cell frequency in GICs after the siRNA
treatment. The experiment was repeated three times. Values represent the mean ± SD. Student’s t test, *P < 0.05. (E-F) Expression of
cleaved Caspase-3 in TS1 cells treated with control (E) or PDGF-B (F) siRNA. Scale bar, 50 μm.
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Figure 6. PDGF-B was indispensable for stemness of GICs. TS1 cells were treated with control or PDGF-B siRNA and expression of HA
and nestin (A-B), HA and SOX2 (C-D), or HA and CNPase (E-F) were analyzed by double immunofluorescence staining. Scale bar, 50 μm.
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GIC Stemness Was Dependent on Expression of PDGF-B
To explore the relationship between PDGF-B expression and the
stemness of GICs, we used siRNA against human PDGF-B to spe-
cifically reduce the viral transduced PDGF-B expression in TS1 cells.
Immunostaining for HA was performed to analyze expression of viral
transduced human PDGF-B protein (Figure 5, A and B). All TS1
cells transfected with control siRNA remained HA positive and
52% of the cells had incorporated BrdU (Figure 5A). In comparison,
cells transfected with PDGF-B siRNA showed an obvious decrease in
HA expression, and all HA-negative cells were also negative for BrdU
incorporation (Figure 5B). However, the transfection efficiency was not
complete, and there were occasional cells still expressing high levels of
HA (data not shown). To further investigate the role of PDGF-B on
the proliferation of GICs, TS1 and TS2 cells were seeded in fresh
GIC medium 48 hours after the first siRNA transfection and the total
cell number was counted on days 1, 4, and 7 (Figure 5C). The result
showed that PDGF-B knockdown could significantly inhibit TS1 (P <
.001) and TS2 (P < .05) cell proliferation when compared with control
siRNA-treated cells (Figure 5C).
The role of PDGF-B for self-renewal ability of GICs was inves-
tigated by limiting dilution assay on siRNA-transfected cells. We
found that inhibition of PDGF-B expression by siRNA could sig-
nificantly reduce the stem frequency in both TS1 and TS2 cells
(Student’s t test, P < .05) compared with control siRNA-treated
cells (Figure 5D).
Immunostaining for cleaved Caspase-3 was performed on control
and PDGF-B siRNA-transfected cells to analyze whether the effects
of PDGF-B knockdown on self-renewal and proliferation could be
due to induction of apoptosis, but we could not find a correlation
between PDGF-B down-regulation and cleaved Caspase-3 expression
(Figure 5, E -F ). To investigate if down-regulation of PDGF-B would
lead to an effect on differentiation of GICs, we analyzed the ex-
pression of stem cell markers nestin and SOX2 together with ex-
pression of HA on PDGF-B knockdown. There was a significant
and almost complete inhibition of both nestin (Figure 6B) and SOX2
(Figure 6D) expression in cells where HA was downregulated. There
was no effect on nestin or SOX2 in control siRNA-treated cells
(Figure 6, A and C ). Expression of GFAP and Tuj1 was analyzed,
but both control and PDGF-B siRNA-treated cells were found to be
negative (data not shown). Interestingly, in cells where PDGF-B was
downregulated, there was a uniform induction of CNPase expression
(Figure 6F ). This implies that the TS1 cells, when cultured under
GIC condition, were kept in an early oligodendrocyte progenitor cell
stage where the expression of PDGF-B is essential for maintenance of
self-renewal.
PDGF-B Depletion Caused GICs to Lose Their
Tumor-Initiating Capacity
The tumor-regenerating capacity of GICs depleted of PDGF-B
was explored by the transfection of TS1 cells with control siRNA
or PDGF-B siRNA followed by injections of 5000 treated cells intra-
cranially into syngeneic newborn mice. Transfection of PDGF-B siRNA
caused a significant inhibition of tumor development (Figure 7A). In
the control siRNA group, all mice developed tumors, whereas there
was a 50% tumor incidence in the PDGF-B siRNA group (Fisher exact
test, P = .044). Histopathology analysis of tumors from the control
siRNA (Figure 7B) and the PDGF-B siRNA (Figure 7C) groups both
showed characteristics of high-grade glioma. PDGF-B expression was
examined by HA staining, and notably, all the tumors from the control
siRNA group (Figure 7D) and the PDGF-B siRNA group (Figure 7E)
were strongly positive for HA. The result suggested that the tumors that
were formed from PDGF-B siRNA-transfected GICs originated from
TS1 cells escaping the siRNA treatment, because we knew that as few as
five GICs could generate a tumor and that the siRNA transfection
efficiency was not complete.
Discussion
Several studies have shown that human glioma cell cultures will be en-
riched for CSCs/CICs that maintain the capacity to generate secondary
tumors with the same phenotype and genotype as the original tumor
when cultured under neurosphere conditions [5–7]. Because there is still
a lack of specific and robust markers defining the CSC population, we
have used the neurosphere culture protocol to isolate, characterize, and
analyze the regulation of GICs derived from experimental gliomas with
regard to self-renewal, proliferation, differentiation, and tumorigenicity.
Figure 7. In vivo tumorigenic capacity of GICs was dependent on
PDGF-B. (A) Tumor incidence in mice transplanted with TS1 cells
treated with control or PDGF-B siRNA. Fisher exact test, *P <
0.05. (B and C) H&E staining of secondary tumors originated from
control (B) or PDGF-B (C) siRNA-treated TS1 cells. Scale bar, 50 μm.
(D and E) HA staining of secondary tumors originated from control
(D) or PDGF-B (E) siRNA-treated TS1 cells. Scale bar, 50 μm.
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We show that by culturing cells as spheres in growth factor-free medium,
GICs can be derived and maintained from high-grade experimental
gliomas and that these tumor cells exhibit all the current criteria defining
CSCs/CICs. Most importantly, this culture condition was highly selec-
tive for tumor-initiating cells where as few as five cells were able to induce
secondary tumors in vivo when orthotopically transplanted into synge-
neic mice, and these tumors exhibited the histopathology and pheno-
type of the primary tumor. The potent tumor-initiating ability of the
cells was supported by the result from the limiting dilution assay, which
showed that the GIC cultures contained a high frequency of cells with
self-renewal ability. Our findings show that experimental RCAS/TV-A–
generated gliomas of the proneural-like subtype contain CSCs, corrobo-
rating a recent report showing that RCAS/TV-A–induced glioma cells
with stem cell–like properties could be enriched in the side population
cells [11].
In line with a study of human glioma cells, which showed that
GICs could be cultured without addition of exogenous growth fac-
tors that was in part mediated by endogenous activation of EGFR
signaling [16], we demonstrated that the experimental GICs driven
by PDGF-B could proliferate and maintain their stemness without
the addition of exogenous EGF and FGF2. However, in our case,
addition of exogenous EGF and/or FGF2 to the medium did not
confer an advantage for self-renewal of GICs, and in long-term cul-
tures, GICs were negatively selected for in the presence of EGF and
FGF2, indicating that NSCs have a faster growth rate than GICs.
The reference cells used throughout the study were obtained by cul-
turing normal NSCs under stem cell condition in defined medium
with addition of EGF and FGF2. Initially, we made extensive efforts
in setting up and culturing these cells under the same conditions as
the GICs, in medium devoid of EGF and FGF2 but with addition of
exogenous PDGF-BB, but found that the NSCs/glial progenitor cells
could not be passaged under these conditions, neither as neuro-
spheres nor as adherently cultured cells on ECM-coated dishes. These
results point to the importance of selecting the appropriate culture
conditions when maintaining GICs in long-term cultures.
We observed an abnormal differentiation capacity of GICs when
subjected to serum-induced differentiation, where they mainly transi-
tioned into cells coexpressing GFAP and Tuj1. This phenomenon of
simultaneous expression of astrocytic and neuronal markers was rarely
found in the normal NSCs that primarily were differentiated into
astrocytes, likely due to the presence of bone morphogenetic pro-
teins in the serum [17]. The coexpression of GFAP and Tuj1 could
be a sign of malignancy because it has also been observed in human
GICs [7]. It has been suggested that a disturbed differentiation
capacity may even contribute to oncogenic transformation. In a
somatic tumor suppressor model where neural stem/progenitor cells
were genetically targeted to become Pten+/− and p53−/−, the target
cells exhibited increased self-renewal capacity and aberrant differen-
tiation properties before the appearance of visible tumors [18]. This
could suggest that abnormal differentiation may serve as a prelude to
tumor formation. Furthermore, we demonstrated that the aberrant
serum-induced differentiation of GICs was reversible and that the cells
could regain their stem cell–like state when cultured in GIC medium
again. This in vitro phenotypic plasticity suggests that GICs may also
change their phenotypes depending on the external tumor environment
in vivo. Recently, it was shown that melanoma-derived cancer stem cells
(CSCs) could display a dynamic phenotype. A group of slow-cycling
melanoma cells with CSC characteristics was identified by JARID1B,
whose expression was dynamically regulated by the external environ-
ment [19]. Depending on culture conditions, JARID1B-negative cells
could give rise to different amount of JARID1B-positive progenies.
Our results from experimental GICs are consistent with the findings
in melanoma and suggest that, contradictory to the conventional uni-
directional CSC model, the stemness of tumor cells may be dynamically
related by the surrounding tumor niche.
We show that our experimental GICs are dependent on PDGF-B
expression for self-renewal and proliferation in vitro and for tumorige-
nicity in vivo. The most obvious rationale for the PDGF dependence of
experimental GICs is that the PDGF-B virus at tumor initiation caused
a selection for target cells expressing PDGFRA and that the resulting
autocrine/paracrine PDGF signaling in combination with Arf de-
ficiency would be sufficient for GICs to occur. The presence of
PDGFR-α in cultured tumor sphere cells supported this view. The re-
sults from the PDGF-B knockdown experiments suggest that PDGF
signaling plays a role in regulating self-renewal of GICs, thus maintain-
ing their stemness. In support, on specific PDGF-B down-regulation,
all cells started to differentiate toward the oligodendrocytic cell lineage
as indicated by uniform CNP expression. This feature has previously
been observed for normal OPCs. In O-2A (oligodendrocyte/type 2
astrocyte) progenitor cells, which can give rise to oligodendrocytes
in vivo, PDGF-B was shown to promote proliferation and motility
and to prevent them from premature differentiation into oligodendro-
cytes [20]. Moreover, depletion of PDGF-B in the GICs significantly
inhibited their tumor initiation capacity. This together with the fact
that there were no HA-negative tumors among the secondary tumors
strongly suggested that GICs were dependent on autocrine PDGF-B
for tumorigenicity. Our results are in line with earlier data, which
showed that when PDGF-B–induced tumor-bearing mice were treated
with the PDGF-receptor inhibitor PTK787, the tumor cells stopped
proliferating, but there was no sign of apoptosis [21]. The effect by
PDGF inhibition on differentiation was not determined in these tumors.
In conclusion, we show that GICs are present in experimental
gliomas in the RCAS/TV-A model, further supporting the relevance
of this model system for the study of glioma. The experimental GICs
were dependent on PDGF signaling for self-renewal, proliferation,
and tumor initiation, and on inhibition of PDGF-B, cells stopped
proliferating and started to uniformly differentiate into oligodendro-
cytes. Our results indicate that patients diagnosed with the proneural
subtype of human glioma that are particularly insensitive to current
therapies may benefit from drugs targeting signaling molecules regu-
lating PDGF-controlled differentiation.
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Figure W1. H&E and immunofluorescence stainings for HA, Ki67, Olig2, Nestin, and GFAP in sections from primary (A) and secondary (B)
gliomas. Scale bar, 50 μm.
